한빛사논문 | BRIC

전홍재 님의 논문 목록

차의과학대학교 분당차병원

CV File 625 kb

- 전홍재(차의과학대학교 분당차병원)
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
- Hepatology, Jul 19 2024, | https://doi.org/10.1097/HEP.0000000000001026
- 2024-07
- 의약학
- 한빛사논문
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after Atezolizumab/Bevacizumab Failure: A real-world study
- Clin. Mol. Hepatol., Volume 30(3); Jul 2024 | https://doi.org/10.3350/cmh.2023.0553
- 2024-07
- 의약학
- 한빛사논문
Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis
- Small, 2023 Jun 28;e2300544 | https://doi.org/10.1002/smll.202300544
- 2023-06
- 의약학
- 한빛사논문
Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma
- Liver Cancer, MAY 25 2023 | DOI: 10.1159/000531182
- 2023-05
- 의약학
- 한빛사논문
High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma-Reply
- JAMA Oncol., 2023 Mar 16 | doi: 10.1001/jamaoncol.2023.0111
- 2023-03
- 의약학
- 한빛사논문
Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
- JAMA Oncol., Published online October 20, 2022 | doi:10.1001/jamaoncol.2022.4733
- 2022-10
- 의약학
- 한빛사논문
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
- Eur. J. Cancer, Volume 175, November 2022, Pages 204-213 | https://doi.org/10.1016/j.ejca.2022.08.024
- 2022-11
- 의약학
- 한빛사논문
Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab
- Clin. Gastroenterol. Hepatol., Available online 6 August 2022 | https://doi.org/10.1016/j.cgh.2022.07.035
- 2022-08
- 의약학
- 한빛사논문
Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
- J. Immunother. Cancer, Online issue publication June 28, 2022 | http://dx.doi.org/10.1136/jitc-2022-004799
- 2022-06
- 의약학
- 한빛사논문
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
- Exp. Mol. Med., Published 11 September 2020 | https://doi.org/10.1038/s12276-020-00500-y
- 2020-09
- 의약학
- 상위피인용논문

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기